معرفی
Sam McNeill is a Research Fellow in Drug Discovery Biology at Monash University, Australia, with an active research profile spanning molecular pharmacology and drug discovery. Her work focuses on G protein-coupled receptors (GPCRs) and their therapeutic applications in metabolic and cardiovascular diseases.
Her primary research interests include GPCR signaling mechanisms, lipid-dependent receptor activation, structural pharmacology of orphan receptors, and peptide therapeutic development. She investigates how regulatory proteins like RGS and GRKs modulate receptor function in cardiometabolic pathways, with emphasis on diabetes and obesity-related disorders. Her methodology integrates biochemical assays, structural analysis, and translational pharmacology to identify novel drug targets.
Analysis of her 2023-2024 publications reveals a cohesive research trajectory centered on GPCR molecular mechanisms and therapeutic optimization. Key themes include structural characterization of receptor activation (e.g., GPR3), modulation of GLP-1R signaling for diabetes treatment, and allosteric control of adenosine receptors. Her work bridges fundamental receptor pharmacology with drug design applications, particularly in stabilizing peptide therapeutics like exenatide.
Dr. McNeill operates within Monash University's collaborative Drug Discovery Biology ecosystem, working alongside interdisciplinary teams in biochemistry, medicinal chemistry, and pharmacology. Her research contributes to Sustainable Development Goals related to good health and well-being through targeted therapeutic development for metabolic diseases.
